vimarsana.com

Page 3 - ப்ளூம்பெர்க் ஜெஂடர் சமத்துவம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ON Semiconductor Named Top 100 Best Corporate Citizens of 20

ON Semiconductor has been named by 3BL Media to its annual 100 Best Corporate Citizens ranking, recognizing outstanding environmental, social and governance (ESG) transparency and performance among the 1,000 largest, U.S. public companies. 3BL Media delivers purpose-driven communications as an editorial platform for the world’s leading companies to inspire and support global sustainable business. This is the first year ON Semiconductor has joined the list, coming in at number 57 and ranking at number five within the semiconductors and semiconductor equipment industry. In June 2021, the company will for the first time also transparently report on its ESG efforts with a performance summary in its annual corporate social responsibility (CSR) report. This is another indicator of ON Semiconductor’s commitment to continuous and measurable improvement of its triple bottom line of people, planet and profit year-over-year.

Big jump in earnings margin generates strong cash ­for Harmony Gold

Big jump in earnings margin generates strong cash ­for Harmony Gold Search Polity Note: Search is limited to the most recent 250 articles. To access earlier articles, click Advanced Search and set an earlier date range. To search for a term containing the & symbol, click Advanced Search and use the search headings and/or in first paragraph options. With. Clear Search Sponsored by Sponsored by 11th May 2021 JOHANNESBURG (miningweekly.com) – Gold mining company Harmony Gold has delivered another strong set of operational results year-on-year on the back of the integration of AngloGold Ashanti assets into its portfolio and a stronger rand per kilogram gold price.

Healthpeak Reports First Quarter 2021 Results

Healthpeak Reports First Quarter 2021 Results News provided by Share this article Share this article DENVER, May 4, 2021 /PRNewswire/  Healthpeak Properties, Inc. (NYSE: PEAK) today announced results for the first quarter ended March 31, 2021. FIRST QUARTER 2021 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS –      Net income of $0.27 per share, NAREIT FFO of $0.07 per share, FFO as Adjusted of $0.40 per share and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 4.3% –      From our February 9, 2021 earnings release through April 30, 2021, closed on an additional $1 billion of senior housing sales including 31 SHOP assets at a blended 2.6% annualized trailing 3-month cap rate $564 million sale of a 12-property SHOP portfolio, totaling 1,043 units, operated by Oakmont Senior Living

IAMGOLD annonce ses résultats du premier trimestre de 2021, génère des flux de trésorerie d exploitation de 102 Millions $; la construction de Côté Gold est sur la bonne voie

IAMGOLD annonce ses résultats du premier trimestre de 2021, génère des flux de trésorerie d exploitation de 102 Millions $; la construction de Côté Gold est sur la bonne voie
zonebourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zonebourse.com Daily Mail and Mail on Sunday newspapers.

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth Group guidance for FY 2021 confirmed

COVID-19 update The COVID-19 situation continues to evolve and is taking differing courses across the multitude of geographies in which Novartis operates. We continue to take strong actions to help address the pandemic. Our primary concerns remain the health and safety of our associates and patients. There continues to be COVID-19 related lockdowns and disruptions in several geographies negatively impacting demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. For Sandoz, COVID-19 resulted in a historically weak cough and cold season and softened retail demand. At present, drug development operations are continuing with manageable disruptions (see the Innovation Review Section of the Condensed Interim Financial Report for further information), with our range of digital technologies allowing us to proactively manage our clinical trials portfolio and rapidly mitigate any disruptions. Our operations remain stable and cash col

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.